Cerevel Therapeutics Holdings Inc / "Executive Compensation" | Tables in SEC filings

CERE Cerevel Therapeutics Holdings Inc

Annual report

A reconciliation of our provision for income tax expenses computed at the statutory federal income tax rate to income taxes as reflected in the consolidated financial statements is as follows:

	For the Year Ended December 31,
	2023			2022			2021
Statutory tax rate		21.0	%		21.0	%		21.0	%
State tax expense, net of federal benefit		7.1	%		6.4	%		6.4	%
Executive compensation		(1.8	)%		(1.2	)%		(2.3	)%
Non-deductible fair value adjustment		—			—			(0.4	)%
Stock based compensation		1.4	%		1.5	%		2.7	%
Tax credits		2.8	%		3.0	%		2.3	%
Other		(0.1	)%		(0.1	)%		0.9	%
Valuation allowance		(30.5	)%		(30.6	)%		(30.6	)%
Effective tax rate		(0.1	)%		0.0	%		0.0	%

Table search / Cerevel Therapeutics Holdings Inc / "Executive Compensation"

1 result

Top filers

Top filing types

Recent filing years